

Guard Therapeutics announces changes in number of shares and votes

Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") today announced that the number of shares and votes in the Company has changed due to the recently completed Rights Issue (for further information, see the Company's press release on April 4, 2025).

Through the Rights Issue, the number of shares and votes increased by 7,872,753 shares, amounting to a total of 20,167,631 shares and votes in Guard Therapeutics. External investors who had undertaken to guarantee the Rights Issue chose to receive the guarantee commission in cash.

For further information, please contact:

Tobias Agervald, CEO

Telephone: +46 8 670 65 51

E-mail: info@guardtherapeutics.com

About Guard Therapeutics

Guard Therapeutics is a Swedish clinical-stage biotechnology company that identifies and develops new therapies for diseases with a large unmet medical need, focusing on different forms of kidney disease. The company's candidate drugs are based on the endogenous protein alpha-1-microglobulin. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm (ticker: GUARD).

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, www.skmg.se.

Attachments

[Guard Therapeutics announces changes in number of shares and votes](#)